Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment

Detalhes bibliográficos
Autor(a) principal: Antonio, Ana Paula do Nascimento
Data de Publicação: 2021
Outros Autores: Nery, Thiago Ribeiro, Manaças, Liliana Rosa Alves, Figueira, Priscila Helena Marietto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/1879
Resumo: Introduction: The evaluation of the causes of interruption of the antineoplastic therapeutic plan allows the development of strategies that increase adherence and positive treatment outcomes. Objective: Outline the clinical profile of the patients with gynecological tumors under intravenous antineoplastic treatment, identifying the risk of interrupting the therapeutic plan. Method: Retrospective and quantitative study (2011-2018), including patients older than 18 years old, with gynecological tumors undergoing antineoplastic treatment. The database was built from the spreadsheets of antineoplastic drug handling at the Chemotherapy Center. The variables collected were: year of treatment, age, type of tumor, purpose of treatment, protocol, medication, dose, start and end of treatment, and treatment interruption. Results: 6,496 patients over 8 years were evaluated. Fifty two percent of the patients presented cervical cancer. Almost forty eight percent (47.6%) showed a palliative treatment purpose for their tumors. Approximately, twenty three percent (22.6%) interrupted the antineoplastic treatment. For adjuvant, curative, and palliative purposes the age range 18-30 presented the highest interruption, respectively 33%, 36% and 41%. The paclitaxel/carboplatin protocol was the most prescribed with a significant percentage of interruption. Conclusion: The findings suggest that there is an association between treatment discontinuation and patients’ age and therapeutic purpose.
id INCA-1_66c3a38c67860290907ec03de23ff7bb
oai_identifier_str oai:rbc.inca.gov.br:article/1879
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic TreatmentEvaluación del Perfil Clinico de Pacientes con Tumores Ginecológicos Sometidos a Tratamiento AntineoplásicoAvaliação do Perfil Clínico de Pacientes com Tumores Ginecológicos em Tratamento Antineoplásiconeoplasias dos genitais femininosefeitos colaterais e reações adversas relacionados a medicamentosantineoplásicossuspensão de tratamentogenital neoplasms, femaledrug-related side effects and adverse reactionsantineoplastic agentswithholding treatmentneoplasias de los genitales femeninosefectos colaterales y reacciones adversas relacionados con medicamentosantineoplásicoprivación de tratamientoIntroduction: The evaluation of the causes of interruption of the antineoplastic therapeutic plan allows the development of strategies that increase adherence and positive treatment outcomes. Objective: Outline the clinical profile of the patients with gynecological tumors under intravenous antineoplastic treatment, identifying the risk of interrupting the therapeutic plan. Method: Retrospective and quantitative study (2011-2018), including patients older than 18 years old, with gynecological tumors undergoing antineoplastic treatment. The database was built from the spreadsheets of antineoplastic drug handling at the Chemotherapy Center. The variables collected were: year of treatment, age, type of tumor, purpose of treatment, protocol, medication, dose, start and end of treatment, and treatment interruption. Results: 6,496 patients over 8 years were evaluated. Fifty two percent of the patients presented cervical cancer. Almost forty eight percent (47.6%) showed a palliative treatment purpose for their tumors. Approximately, twenty three percent (22.6%) interrupted the antineoplastic treatment. For adjuvant, curative, and palliative purposes the age range 18-30 presented the highest interruption, respectively 33%, 36% and 41%. The paclitaxel/carboplatin protocol was the most prescribed with a significant percentage of interruption. Conclusion: The findings suggest that there is an association between treatment discontinuation and patients’ age and therapeutic purpose.Introducción: La evaluación de las causas de interrupción del plan terapéutico antineoplásico permite el desarrollo de estrategias que aumentan la adherencia y los resultados positivos del tratamiento. Objetivo: Delinear el perfil clínico de las pacientes con tumores ginecológicos, en tratamiento antineoplásico intravenoso, identificando el riesgo de interrupción del plan terapéutico. Método: Estudio retrospectivo y cuantitativo (2011-2018), que incluyó a pacientes mayores de 18 años, con tumores ginecológicos en tratamiento antineoplásico. La base de datos se construyó a partir de las hojas de cálculo del manejo de fármacos antineoplásicos en el Centro de Quimioterapia. Las variables recogidas fueron: año de tratamiento, edad, tipo de tumor, finalidad del tratamiento, protocolo, medicación, dosis, inicio y finalización del tratamiento e interrupción del mismo. Resultados: Se evaluaron 6.496 pacientes durante los ocho años. El 52% de las pacientes presentó cáncer de cuello uterino. Casi el 48% (47,6%) mostró un propósito de tratamiento paliativo para sus tumores. Aproximadamente, el 23% (22,6%) interrumpió el tratamiento antineoplásico. Para fines adyuvantes, curativos y paliativos, el rango de edad de 18 a 30 años presentó la mayor interrupción, respectivamente 33%, 36% y 41%. El paclitaxel/carboplatino fue el más prescrito con un porcentaje significativo de interrupción. Conclusión: Nuestros hallazgos sugieren que existe una asociación entre la interrupción del tratamiento y la edad de los pacientes y el propósito terapéutico.Introdução: A avaliação das causas de interrupção do plano terapêutico antineoplásico permite a elaboração de estratégias que aumentem a adesão e os desfechos positivos do tratamento. Objetivo: Traçar o perfil clínico das pacientes com tumores ginecológicos, em tratamento antineoplásico intravenoso, identificando o risco de interrupção do plano terapêutico. Método: Estudo retrospectivo e quantitativo (2011-2018), incluindo pacientes maiores de 18 anos, com tumores ginecológicos em tratamento antineoplásico. O banco de dados foi construído a partir das planilhas de controle de antineoplásicos da Central de Quimioterapia. As variáveis coletadas foram ano de tratamento, idade, tipo de tumor, finalidade do tratamento, protocolo, medicamento, dose, início e término do tratamento e interrupção do tratamento. Resultados: Avaliaram-se 6.496 pacientes ao longo de oito anos. Cinquenta e dois por cento das pacientes apresentavam câncer cervical. Quase 48% (47,6%) apresentaram uma finalidade de tratamento paliativo para seus tumores. Aproximadamente 23% (22,6%) interromperam o tratamento antineoplásico. Para fins adjuvantes, curativos e paliativos, a faixa etária de 18 a 30 anos apresentou a maior interrupção, respectivamente 33%, 36% e 41%. O protocolo paclitaxel/carboplatina foi o mais prescrito com percentual significativo de interrupção. Conclusão: Os achados sugerem que exista uma associação entre a suspensão do tratamento e a idade dos pacientes e a finalidade terapêutica.INCA2021-12-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdftext/htmlhttps://rbc.inca.gov.br/index.php/revista/article/view/187910.32635/2176-9745.RBC.2022v68n1.1879Revista Brasileira de Cancerologia; Vol. 68 No. 1 (2022): Jan./Feb./Mar.; e-011879Revista Brasileira de Cancerologia; Vol. 68 Núm. 1 (2022): ene./feb./mar.; e-011879Revista Brasileira de Cancerologia; v. 68 n. 1 (2022): jan./fev./mar.; e-0118792176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAenghttps://rbc.inca.gov.br/index.php/revista/article/view/1879/1559https://rbc.inca.gov.br/index.php/revista/article/view/1879/1914Copyright (c) 2021 Revista Brasileira de Cancerologiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAntonio, Ana Paula do Nascimento Nery, Thiago Ribeiro Manaças, Liliana Rosa Alves Figueira, Priscila Helena Marietto 2023-07-27T13:35:21Zoai:rbc.inca.gov.br:article/1879Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-07-27T13:35:21Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
Evaluación del Perfil Clinico de Pacientes con Tumores Ginecológicos Sometidos a Tratamiento Antineoplásico
Avaliação do Perfil Clínico de Pacientes com Tumores Ginecológicos em Tratamento Antineoplásico
title Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
spellingShingle Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
Antonio, Ana Paula do Nascimento
neoplasias dos genitais femininos
efeitos colaterais e reações adversas relacionados a medicamentos
antineoplásicos
suspensão de tratamento
genital neoplasms, female
drug-related side effects and adverse reactions
antineoplastic agents
withholding treatment
neoplasias de los genitales femeninos
efectos colaterales y reacciones adversas relacionados con medicamentos
antineoplásico
privación de tratamiento
title_short Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
title_full Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
title_fullStr Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
title_full_unstemmed Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
title_sort Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment
author Antonio, Ana Paula do Nascimento
author_facet Antonio, Ana Paula do Nascimento
Nery, Thiago Ribeiro
Manaças, Liliana Rosa Alves
Figueira, Priscila Helena Marietto
author_role author
author2 Nery, Thiago Ribeiro
Manaças, Liliana Rosa Alves
Figueira, Priscila Helena Marietto
author2_role author
author
author
dc.contributor.author.fl_str_mv Antonio, Ana Paula do Nascimento
Nery, Thiago Ribeiro
Manaças, Liliana Rosa Alves
Figueira, Priscila Helena Marietto
dc.subject.por.fl_str_mv neoplasias dos genitais femininos
efeitos colaterais e reações adversas relacionados a medicamentos
antineoplásicos
suspensão de tratamento
genital neoplasms, female
drug-related side effects and adverse reactions
antineoplastic agents
withholding treatment
neoplasias de los genitales femeninos
efectos colaterales y reacciones adversas relacionados con medicamentos
antineoplásico
privación de tratamiento
topic neoplasias dos genitais femininos
efeitos colaterais e reações adversas relacionados a medicamentos
antineoplásicos
suspensão de tratamento
genital neoplasms, female
drug-related side effects and adverse reactions
antineoplastic agents
withholding treatment
neoplasias de los genitales femeninos
efectos colaterales y reacciones adversas relacionados con medicamentos
antineoplásico
privación de tratamiento
description Introduction: The evaluation of the causes of interruption of the antineoplastic therapeutic plan allows the development of strategies that increase adherence and positive treatment outcomes. Objective: Outline the clinical profile of the patients with gynecological tumors under intravenous antineoplastic treatment, identifying the risk of interrupting the therapeutic plan. Method: Retrospective and quantitative study (2011-2018), including patients older than 18 years old, with gynecological tumors undergoing antineoplastic treatment. The database was built from the spreadsheets of antineoplastic drug handling at the Chemotherapy Center. The variables collected were: year of treatment, age, type of tumor, purpose of treatment, protocol, medication, dose, start and end of treatment, and treatment interruption. Results: 6,496 patients over 8 years were evaluated. Fifty two percent of the patients presented cervical cancer. Almost forty eight percent (47.6%) showed a palliative treatment purpose for their tumors. Approximately, twenty three percent (22.6%) interrupted the antineoplastic treatment. For adjuvant, curative, and palliative purposes the age range 18-30 presented the highest interruption, respectively 33%, 36% and 41%. The paclitaxel/carboplatin protocol was the most prescribed with a significant percentage of interruption. Conclusion: The findings suggest that there is an association between treatment discontinuation and patients’ age and therapeutic purpose.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-23
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1879
10.32635/2176-9745.RBC.2022v68n1.1879
url https://rbc.inca.gov.br/index.php/revista/article/view/1879
identifier_str_mv 10.32635/2176-9745.RBC.2022v68n1.1879
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1879/1559
https://rbc.inca.gov.br/index.php/revista/article/view/1879/1914
dc.rights.driver.fl_str_mv Copyright (c) 2021 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/html
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 68 No. 1 (2022): Jan./Feb./Mar.; e-011879
Revista Brasileira de Cancerologia; Vol. 68 Núm. 1 (2022): ene./feb./mar.; e-011879
Revista Brasileira de Cancerologia; v. 68 n. 1 (2022): jan./fev./mar.; e-011879
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042232274976768

Registros relacionados